Search results
Results from the WOW.Com Content Network
The aims of EULAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with musculoskeletal diseases by the ...
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. [1] It targets interferon a. [2] Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials. [3] [4] [5]
SLE is one of several diseases known as "the great imitator" because it often mimics or is mistaken for other illnesses. [12] SLE is a classical item in differential diagnosis, [13] because SLE symptoms vary widely and come and go unpredictably. Diagnosis can thus be elusive, with some people having unexplained symptoms of SLE for years before ...
Here are the contribution limits for HSAs in 2024 and 2025, along with other key HSA eligibility requirements. ... multiplied by 7/12. ... care plan to make a full year’s worth of HSA ...
The following is a list of highest-grossing films in Nepal, with gross revenue in Nepali Rupees.The prominent films released in Nepal before 2075 BS (2018 CE) had no official tracking of figures and thus contains generally accepted figures provided by producers, distributors and media reports.
Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE) and childhood-onset systemic lupus erythematosus which is a more severe form of SLE that develops in children up to 18 years old; both are autoimmune diseases. [3] [4] It is a type of glomerulonephritis in which the glomeruli become inflamed.
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.. Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system" [6] via a process called trogocytosis. [3]
[nb 1] Nepal made its first submission in 1999. The Foreign Language Film award is handed out annually by the United States Academy of Motion Picture Arts and Sciences to a feature-length motion picture produced outside the United States that contains primarily non- English dialogue. [ 3 ]